Systemic Lupus Erythematosus and Common Variable Immunodeficiency

Azar, Antoine; Aldaoud, Nawras; Hardenbergh, Dylan; Krimins, Rebecca; Son, James; Shiroky, Jennifer; Timlin, Homa

doi:10.1097/rhu.0000000000001709

Cited by 4 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic lupus erythematosus (SLE) is an autoimmune-mediated systemic inflammatory disease ( 116 ). Lupus nephritis (LN) is one of the most common complications of SLE and a major predictor of poor prognosis ( 117 ). Therefore, in-depth research on the pathogenesis of lupus nephritis will bring hope for future precise treatment that directly targets specific cells, autoantibodies, cytokines and chemokines to regulate inflammation and tissue damage ( 118 ).…”

Section: Iguratimod In the Treatment Of Rheumatic Bone Diseases And A...mentioning

confidence: 99%

Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases

Long,

Zeng,

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Autoimmune diseases are affected by complex pathophysiology involving multiple cell types, cytokines, antibodies and mimicking factors. Different drugs are used to improve these autoimmune responses, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, antibodies, and small molecule drugs (DMARDs), which are prevalent clinically in the treatment of rheumatoid arthritis (RA), etc. However, low cost-effectiveness, reduced efficacy, adverse effects, and patient non-response are unattractive factors driving the development of new drugs such as iguratimod. As a new disease-modifying antirheumatic drug, iguratimod has pharmacological activities such as regulating autoimmune disorders, inflammatory cytokines, regulating immune cell activation, differentiation and proliferation, improving bone metabolism, and inhibiting fibrosis. In recent years, clinical studies have found that iguratimod is effective in the treatment of RA, SLE, IGG4-RD, Sjogren ‘s syndrome, ankylosing spondylitis, interstitial lung disease, and other autoimmune diseases and rheumatic diseases. The amount of basic and clinical research on other autoimmune diseases is also increasing. Therefore, this review systematically reviews the latest relevant literature in recent years, reviews the research results in recent years, and summarizes the research progress of iguratimod in the treatment of related diseases. This review highlights the role of iguratimod in the protection of autoimmune and rheumatic bone and related immune diseases. It is believed that iguratimod’s unique mode of action and its favorable patient response compared to other DMARDs make it a suitable antirheumatic and bone protective agent in the future.

show abstract

Section: Iguratimod In the Treatment Of Rheumatic Bone Diseases And A...mentioning

confidence: 99%

Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases

Long,

Zeng,

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…CVID and SIgAD are associated with rheumatologic manifestations, of which chronic inflammatory arthritis is the most common, as well as juvenile arthritis, rheumatoid arthritis, psoriatic arthritis; disorders of the connective tissue like systemic lupus erythematous [217] and Sjögren's syndrome; and vasculitis like Behçet's disease. In these patients, autoreactive B cells are postulated to be involved, probably as a consequence of the reduced BCR heterogeneity.…”

Section: Autoimmune Manifestations In Cvid and Sigadmentioning

confidence: 99%

“…Systemic lupus erythematosus has been associated with both [227] SIgAD [228] and CVID [217,229]. SIgAD may pose a risk for a 35-fold increased frequency of SLE [230].…”

Section: Autoimmune Manifestations In Cvid and Sigadmentioning

confidence: 99%

Common Variable Immunodeficiency and Selective IgA Deficiency: Focus on Autoimmune Manifestations and Their Pathogenesis

Sircana,

Vidili,

Gidaro

et al. 2023

IJTM

View full text Add to dashboard Cite

Inborn errors of immunity (IEI) are multifaced diseases which can present with a variety of phenotypes, ranging from infections to autoimmunity, lymphoproliferation, and neoplasms. In recent decades, research has investigated the relationship between autoimmunity and IEI. Autoimmunity is more prevalent in primary humoral immunodeficiencies than in most other IEI and it can even be their first manifestation. Among these, the two most common primary immunodeficiencies are selective IgA deficiency and common variable immunodeficiency. More than half of the patients with these conditions develop non-infectious complications due to immune dysregulation: autoimmune, autoinflammatory, allergic disorders, and malignancies. Around 30% of these patients present with autoimmune phenomena, such as cytopenia, gastrointestinal and respiratory complications, and endocrine and dermatologic features. Complex alterations of the central and peripheral mechanisms of tolerance are involved, affecting mainly B lymphocytes but also T cells and cytokines. Not only the immunophenotype but also advances in genetics allow us to diagnose monogenic variants of these diseases and to investigate the pathogenetic basis of the immune dysregulation. The diagnosis and therapy of the primary humoral immunodeficiencies has been mostly focused on the infectious complications, while patients with predominant features of immune dysregulation and autoimmunity still present a challenge for the clinician and an opportunity for pathogenetic and therapeutic research.

show abstract

Auto-immuno-deficiency syndromes

Houen

2024

Autoimmunity Reviews

View full text Add to dashboard Cite

Systemic Lupus Erythematosus and Common Variable Immunodeficiency

Cited by 4 publications

References 23 publications

Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases

Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases

Common Variable Immunodeficiency and Selective IgA Deficiency: Focus on Autoimmune Manifestations and Their Pathogenesis

Auto-immuno-deficiency syndromes

Contact Info

Product

Resources

About